Publications

5674 Results

A phase 3 randomized study comparing perioperative nivolumab vs. observation in patients with localized renal cell carcinoma undergoing nephrectomy (PROSPER RCC, EA8143)

Authors
LC Harshman;M Puligandla;N Haas;M Allaf;D McDermott;S Signoretti;R Gupta;TK Choueiri;P Lara;A Kapoor;D Heng;B Shuch;M Jewett;D George;D Michaelson;R Bhat;E Van Allen;V Master;MA Carducci
Journal / Conference
J Clin Oncol 35, 2017 (suppl; abstr TPS4596);American Society of Clinical Oncology (ASCO) Annual Meeting (June 2-6, 2017, Chicago, IL), poster session (TIP)
Year
2017
Research Committee(s)
Genitourinary
Study Number(s)
CTSU/EA8143

A randomized, phase II efficacy assessment of multiple MET kinase inhibitors (Cabozantinib [NSC #761968], crizotinib [NSC #749005], savolitinib [NSC #785348], and sunitinib [NSC #736511]) in metastatic papillary renal carcinoma (PAPMET): SWOG S1500, NCT02761057

Authors
S Pal;C Tangen;IM Thompson;B Shuch;N Balzer-Haas;DJ George;M Stein;M Plets;P Lara
Journal / Conference
J Clin Oncol 35, 2017 (suppl; abstr TPS4599); American Society of Clinical Oncology Annual Meeting (June 2-6, 2017, Chicago, IL), poster session
Year
2017
Research Committee(s)
Genitourinary
Study Number(s)
S1500

SWOG S1605: phase II trial of atezolizumab in BCG-unresponsive non-muscle invasive bladder cancer

Authors
P Singh;C Tangen;SP Lerner;D McConkey;M Plets;MS Lucia;ME Woods;T Bivilacqua;W Kassouf;R Bangs;IM Thompson;P Black
Journal / Conference
J Clin Oncol 35, 2017 (suppl; abstr TPS4591); American Society of Clinical Oncology Annual Meeting (June 2-6, 2017, Chicago, IL), poster session
Year
2017
Research Committee(s)
Genitourinary
Study Number(s)
S1605

S1605: phase II trial of atezolizumab in BCG-unresponsive non-muscle invasive bladder cancer

Authors
P Singh;SP Lerner;D McConkey;MS Lucia;W Kassouf;ME Woods;T Bivilacqua;M Plets;C Tangen;P Black
Journal / Conference
Canadian Urological Association Journal June Vol 11(6Suppl4): abst. MP-04.15; Canadian Urological Association annual meeting (June 24-27, 2017, Toronto, Ontario, Canada), poster
Year
2017
Research Committee(s)
Genitourinary
Study Number(s)
S1605

A genetic risk-stratified, phase II study of fludarabine/antibody combinations in symptomatic, untreated chronic lymphocytic leukemia (CLL): final results of Cancer and Leukemia Group B (CALGB) 10404

Authors
A Ruppert;J Byrd;N Heerema;MR Smith;J Godwin;S Couban;T Fehniger;M Thirman;A Halvorson;BL Peterson;MS Tallman;FR Appelbaum;RM Stone
Journal / Conference
J Clin Oncol 35, 2017 (suppl; abstr 7503); American Society of Clinical OncologyAnnual Meeting (June 2-6, 2017, Chicago, IL), oral presentation
Year
2017
Research Committee(s)
Leukemia
Study Number(s)
C10404

A phase II study of Durvalumab (MEDI4736) for previously treated patients with stage IV squamous NSCLC (SqNSCLC): Lung-MAP Sub-study SWOG S1400A

Authors
V Papadimitrakopoulou;M Redman;H Borghaei;SN Wagar;F Robert;GJ Kiefer;S McDonough;R Herbst;K Kelly;D Gandara
Journal / Conference
Annals of Oncology 28 (suppl_2): mdx091.003; European Lung Cancer Conference (May 5-7, 2017, Geneva, Switzerland), oral presentation
Year
2017
Research Committee(s)
Lung
Study Number(s)
S1400A

A phase II study of gdc-0032 (taselisib) for previously treated pi3k positive patients with stage iv squamous cell lung cancer (sqNSCLC): lung-map sub-study swog s1400B

Authors
JL Wade;M Redman;C Langer;C Aggarwal;JD Bradley;J Crawford;J Miao;K Griffin;R Herbst;K Kelly;D Gandara
Journal / Conference
J Clin Oncol 35 (suppl; abstr 9054); ASCO Annual Meeting (June 2-6, 2017, Chicago, IL), poster session
Year
2017
Research Committee(s)
Lung
Study Number(s)
S1400B

A phase II study of palbociclib (p) for previously treated cell cycle gene alteration positive patients (pts) with stage IV squamous cell lung cancer (scc): lung-map sub-study swog S1400C

Authors
M Edelman;M Redman;KS Albain;E McGary;N Rafique;D Petro;S Wagar;K Griffin;J Miao;V Papadimitrakopoulou;K Kelly;D Gandara;R Herbst
Journal / Conference
J Clin Oncol 35 (suppl; abstr 9056); ASCO Annual Meeting (June 2-6, 2017, Chicago, IL), poster session
Year
2017
Research Committee(s)
Lung
Study Number(s)
S1400C

SWOG S1221: A phase 1 dose escalation study co-targeting MAPK-dependent and MAPK-independent BRAF inhibitor resistance in BRAF mutant advanced solid tumors with dabrafenib, trametinib, and GSK2141795 (ClinicalTrials.gov NCT01902173)

Authors
A Algazi;J Moon;B Chmielowski;RS Lo;K Kendra;C Lao;K Lewis;R Gonzalez;KB Kim;JE Godwin;BD Curti;M Othus;A Ribas
Journal / Conference
J Clin Oncol 35, 2017 (suppl; abstr 2578); American Society of Clinical Oncology Annual Meeting (June 2-6, 2017, Chicago, IL), poster session
Year
2017
Research Committee(s)
Melanoma
Study Number(s)
S1221

Two-year trends and predictors of taxane-induced neuropathy in women enrolled in a randomized trial of acetyl-l-carnitine (SWOG S0715; NCT00775645) (http://abstracts.asco.org/199/AbstView_199_184547.html)

Authors
DL Hershman;JM Unger;KD Crew;C Ebnesajjad;H Greenlee;C Moinpour;L Minasian;D Lew;JL Wade;KS Albain;MJ Fisch;NL Henry
Journal / Conference
J Clin Oncol 35, 2017 (suppl; abstr 10093);American Society of Clinical Oncology Annual Meeting (June 2-6, 2017, Chicago, IL), poster
Year
2017
Research Committee(s)
Symptom Management and Survivorship
Study Number(s)
S0715